#everest medicines

Collection of everest medicines news, found 5 news.

Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia

Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia

  • 17th June 2026

 Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with ...

Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio

Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio

  • 11th June 2026

 Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare ...

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology

  • 11th June 2026

 Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel ...

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

  • 5th June 2026

 Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with ...

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

  • 5th June 2026

 Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration ...